Kristina M. Angelo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kristina M. Angelo has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Davidson H. Hamer
Department of Global Health, Boston University School of Public Health, Boston, MA, USA
5 shared publications - Michael Libman
J. D. Maclean Centre for Tropical Medicine, McGill University Health Centre , Montreal QC H4A 3J1
4 shared publications - Emmanuel Bottieau
Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
3 shared publications - Philippe Gautret
Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France
3 shared publications - Alexandre Duvignaud
Department of Infectious Diseases and Tropical Medicine, Division of Tropical Medicine and Clinical International Health, CHU de Bordeaux, Bordeaux, France
2 shared publications Camilla Rothe
Department of Infectious Diseases and Tropical Medicine, Ludwig-Maximilians-Universität München, Munich, Germany (C.R.)
2 shared publications
Latest Publications
- 1 September 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (9) , 1269-1270
A Zebra Among the Horses: Clinical Implications of Malaria in the United States
- 1 September 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (9) , 1269-1270
A Zebra Among the Horses: Clinical Implications of Malaria in the United States
- 1 July 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (7) , 940-948
Clinical Characteristics and Outcomes Among Travelers With Severe Dengue
Dengue virus is a flavivirus transmitted by Aedes mosquitoes and is an important cause of illness worldwide. Data on the severity of travel-associated dengue illness are limited. To describe the epidemiology, clinical characteristics, and outcomes among international travelers with severe dengue or dengue with warning signs as defined by the 2009 World Health Organization classification (that is, complicated dengue). Retrospective chart review and analysis of travelers with complicated dengue reported to GeoSentinel from January 2007 through July 2022. 20 of 71 international GeoSentinel sites. Returning travelers with complicated dengue. Routinely collected surveillance data plus chart review with abstraction of clinical information using predefined grading criteria to characterize the manifestations of complicated dengue. Of 5958 patients with dengue, 95 (2%) had complicated dengue. Eighty-six (91%) patients had a supplemental questionnaire completed. Eighty-five of 86 (99%) patients had warning signs, and 27 (31%) were classified as severe. Median age was 34 years (range, 8 to 91 years); 48 (56%) were female. Patients acquired dengue most frequently in the Caribbean (n = 27 [31%]) and Southeast Asia (n = 21 [24%]). Frequent reasons for travel were tourism (46%) and visiting friends and relatives (32%). Twenty-one of 84 (25%) patients had comorbidities. Seventy-eight (91%) patients were hospitalized. One patient died of nondengue-related illnesses. Common laboratory findings and signs were thrombocytopenia (78%), elevated aminotransferase (62%), bleeding (52%), and plasma leakage (20%). Among severe cases, ophthalmologic pathology (n = 3), severe liver disease (n = 3), myocarditis (n = 2), and neurologic symptoms (n = 2) were reported. Of 44 patients with serologic data, 32 confirmed cases were classified as primary dengue (IgM+/IgG-) and 12 as secondary (IgM-/IgG+) dengue. Data for some variables could not be retrieved by chart review for some patients. The generalizability of our observations may be limited. Complicated dengue is relatively rare in travelers. Clinicians should monitor patients with dengue closely for warning signs that may indicate progression to severe disease. Risk factors for developing complications of dengue in travelers need further prospective study. Centers for Disease Control and Prevention, International Society of Travel Medicine, Public Health Agency of Canada, and GeoSentinel Foundation.
- 1 July 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (7) , 940-948
Clinical Characteristics and Outcomes Among Travelers With Severe Dengue
Dengue virus is a flavivirus transmitted by Aedes mosquitoes and is an important cause of illness worldwide. Data on the severity of travel-associated dengue illness are limited. To describe the epidemiology, clinical characteristics, and outcomes among international travelers with severe dengue or dengue with warning signs as defined by the 2009 World Health Organization classification (that is, complicated dengue). Retrospective chart review and analysis of travelers with complicated dengue reported to GeoSentinel from January 2007 through July 2022. 20 of 71 international GeoSentinel sites. Returning travelers with complicated dengue. Routinely collected surveillance data plus chart review with abstraction of clinical information using predefined grading criteria to characterize the manifestations of complicated dengue. Of 5958 patients with dengue, 95 (2%) had complicated dengue. Eighty-six (91%) patients had a supplemental questionnaire completed. Eighty-five of 86 (99%) patients had warning signs, and 27 (31%) were classified as severe. Median age was 34 years (range, 8 to 91 years); 48 (56%) were female. Patients acquired dengue most frequently in the Caribbean (n = 27 [31%]) and Southeast Asia (n = 21 [24%]). Frequent reasons for travel were tourism (46%) and visiting friends and relatives (32%). Twenty-one of 84 (25%) patients had comorbidities. Seventy-eight (91%) patients were hospitalized. One patient died of nondengue-related illnesses. Common laboratory findings and signs were thrombocytopenia (78%), elevated aminotransferase (62%), bleeding (52%), and plasma leakage (20%). Among severe cases, ophthalmologic pathology (n = 3), severe liver disease (n = 3), myocarditis (n = 2), and neurologic symptoms (n = 2) were reported. Of 44 patients with serologic data, 32 confirmed cases were classified as primary dengue (IgM+/IgG-) and 12 as secondary (IgM-/IgG+) dengue. Data for some variables could not be retrieved by chart review for some patients. The generalizability of our observations may be limited. Complicated dengue is relatively rare in travelers. Clinicians should monitor patients with dengue closely for warning signs that may indicate progression to severe disease. Risk factors for developing complications of dengue in travelers need further prospective study. Centers for Disease Control and Prevention, International Society of Travel Medicine, Public Health Agency of Canada, and GeoSentinel Foundation.
- Open Access
- 26 March 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (4)
A country classification system to inform rabies prevention guidelines and regulations
Background: Assessing the global risk of rabies exposure is a complicated task requiring individual risk assessments, knowledge of rabies epidemiology, surveillance capacity and accessibility of rabies biologics on a national and regional scale. In many parts of the world, availability of this information is limited and when available is often dispersed across multiple sources. This hinders the process of making evidence-based health and policy recommendations to prevent the introduction and spread of rabies. Methods: CDC conducted a country-by-country qualitative assessment of risk and protective factors for rabies to develop an open-access database of core metrics consisting of the presence of lyssaviruses (specifically canine or wildlife rabies virus variants or other bat lyssaviruses), access to rabies immunoglobulins and vaccines, rabies surveillance capacity and canine rabies control capacity. Using these metrics, we developed separate risk scoring systems to inform rabies prevention guidance for travelers and regulations for the importation of dogs. Both scoring systems assigned higher risk to countries with enzootic rabies (particularly canine rabies), and the risk scoring system for travelers also considered protective factors such as the accessibility of rabies biologics for post-exposure prophylaxis. Cumulative scores were calculated across the assessed metrics to assign a risk value of low, moderate or high. Results: A total of 240 countries, territories and dependencies were assessed, for travelers, 116 were identified as moderate to high risk and 124 were low or no risk; for canine rabies virus variant importation, 111 were identified as high-risk and 129 were low or no risk. Conclusions: We developed a comprehensive and easily accessible source of information for assessing the rabies risk for individual countries that included a database of rabies risk and protective factors based on enzootic status and availability of biologics, provided a resource that categorizes risk by country and provided guidance based on these risk categories for travelers and importers of dogs into the United States.
- 26 March 2022
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 29 (4)
Open AccessA country classification system to inform rabies prevention guidelines and regulations
Background: Assessing the global risk of rabies exposure is a complicated task requiring individual risk assessments, knowledge of rabies epidemiology, surveillance capacity and accessibility of rabies biologics on a national and regional scale. In many parts of the world, availability of this information is limited and when available is often dispersed across multiple sources. This hinders the process of making evidence-based health and policy recommendations to prevent the introduction and spread of rabies. Methods: CDC conducted a country-by-country qualitative assessment of risk and protective factors for rabies to develop an open-access database of core metrics consisting of the presence of lyssaviruses (specifically canine or wildlife rabies virus variants or other bat lyssaviruses), access to rabies immunoglobulins and vaccines, rabies surveillance capacity and canine rabies control capacity. Using these metrics, we developed separate risk scoring systems to inform rabies prevention guidance for travelers and regulations for the importation of dogs. Both scoring systems assigned higher risk to countries with enzootic rabies (particularly canine rabies), and the risk scoring system for travelers also considered protective factors such as the accessibility of rabies biologics for post-exposure prophylaxis. Cumulative scores were calculated across the assessed metrics to assign a risk value of low, moderate or high. Results: A total of 240 countries, territories and dependencies were assessed, for travelers, 116 were identified as moderate to high risk and 124 were low or no risk; for canine rabies virus variant importation, 111 were identified as high-risk and 129 were low or no risk. Conclusions: We developed a comprehensive and easily accessible source of information for assessing the rabies risk for individual countries that included a database of rabies risk and protective factors based on enzootic status and availability of biologics, provided a resource that categorizes risk by country and provided guidance based on these risk categories for travelers and importers of dogs into the United States.
- Open Access
- 5 March 2020
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 102 (3) , 491-493
Putting Guidance into Practice: Interpretation of the Oral Cholera Vaccine Recommendations for U.S. Travelers
The American Committee on Immunization Practices recommends the use of the oral cholera vaccine (OCV) in international travelers aged 18–64 years who visit areas of active cholera transmission. CDC Travelers’ Health Branch currently tracks areas of active cholera transmission and posts this information on their country-specific destination web pages at https://wwwnc.cdc.gov/travel/destinations/list. Lessons learned from a webinar conducted among health care providers have led to improvements in how CDC shares information on the OCV. Here, we summarize the major considerations for providers offering the OCV to U.S. travelers and indicate where they can find more information.
- 5 March 2020
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 102 (3) , 491-493
Open AccessPutting Guidance into Practice: Interpretation of the Oral Cholera Vaccine Recommendations for U.S. Travelers
The American Committee on Immunization Practices recommends the use of the oral cholera vaccine (OCV) in international travelers aged 18–64 years who visit areas of active cholera transmission. CDC Travelers’ Health Branch currently tracks areas of active cholera transmission and posts this information on their country-specific destination web pages at https://wwwnc.cdc.gov/travel/destinations/list. Lessons learned from a webinar conducted among health care providers have led to improvements in how CDC shares information on the OCV. Here, we summarize the major considerations for providers offering the OCV to U.S. travelers and indicate where they can find more information.
- Open Access
- 28 January 2020
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 27 (7)
Traveller exposures to animals: a GeoSentinel analysis
Human coexistence with other animals can result in both intentional and unintentional contact with a variety of mammalian and non-mammalian species. International travellers are at risk for such encounters; travellers risk injury, infection and possibly death from domestic and wild animal bites, scratches, licks and other exposures. The aim of the present analysis was to understand the diversity and distribution of animal-related exposures among international travellers. Data from January 2007 through December 2018 from the GeoSentinel Surveillance Network were reviewed. Records were included if the exposure was non-migration travel with a diagnosis of an animal (dog, cat, monkey, snake or other) bite or other exposure (non-bite); records were excluded if the region of exposure was not ascertainable or if another, unrelated acute diagnosis was reported. A total of 6470 animal exposures (bite or non-bite) were included. The majority (71%) occurred in Asia. Travellers to 167 countries had at least one report of an animal bite or non-bite exposure. The majority (76%) involved dogs, monkeys and cats, although a wide range of wild and domestic species were involved. Almost two-thirds (62.6%) of 4395 travellers with information available did not report a pretravel consultation with a healthcare provider. Minimizing bites and other animal exposures requires education (particularly during pretravel consultations) and behavioral modification. These should be supplemented by the use of pre-exposure rabies vaccination for travellers to high-risk countries (especially to those with limited access to rabies immunoglobulin), as well as encouragement of timely (in-country) post-exposure prophylaxis for rabies and Macacine alphaherpesvirus 1 (herpesvirus B) when warranted.
- 28 January 2020
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 27 (7)
Open AccessTraveller exposures to animals: a GeoSentinel analysis
Human coexistence with other animals can result in both intentional and unintentional contact with a variety of mammalian and non-mammalian species. International travellers are at risk for such encounters; travellers risk injury, infection and possibly death from domestic and wild animal bites, scratches, licks and other exposures. The aim of the present analysis was to understand the diversity and distribution of animal-related exposures among international travellers. Data from January 2007 through December 2018 from the GeoSentinel Surveillance Network were reviewed. Records were included if the exposure was non-migration travel with a diagnosis of an animal (dog, cat, monkey, snake or other) bite or other exposure (non-bite); records were excluded if the region of exposure was not ascertainable or if another, unrelated acute diagnosis was reported. A total of 6470 animal exposures (bite or non-bite) were included. The majority (71%) occurred in Asia. Travellers to 167 countries had at least one report of an animal bite or non-bite exposure. The majority (76%) involved dogs, monkeys and cats, although a wide range of wild and domestic species were involved. Almost two-thirds (62.6%) of 4395 travellers with information available did not report a pretravel consultation with a healthcare provider. Minimizing bites and other animal exposures requires education (particularly during pretravel consultations) and behavioral modification. These should be supplemented by the use of pre-exposure rabies vaccination for travellers to high-risk countries (especially to those with limited access to rabies immunoglobulin), as well as encouragement of timely (in-country) post-exposure prophylaxis for rabies and Macacine alphaherpesvirus 1 (herpesvirus B) when warranted.
- 1 November 2019
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 32, 101504
International mass gatherings and travel-associated illness: A GeoSentinel cross-sectional, observational study
- 1 November 2019
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 32, 101504
International mass gatherings and travel-associated illness: A GeoSentinel cross-sectional, observational study
- Open Access
- 20 June 2019
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 26 (6)
The rise in travel-associated measles infections—GeoSentinel, 2015–2019
Measles remains a global threat to human health. In 2018, the World Health Organization (WHO) reported over 328 000 measles cases among 184 WHO member states, with the European Region reporting the most cases (25.6%). 1 From January to March 2019, reported cases rose 300% in comparison to the same months in 2018. 2 Low vaccination coverage for measles is presumed to be responsible for this recent increase. 3–5 International travelers to measles-affected countries are at risk for infection and may contribute to disease importation. 3, 4
- 20 June 2019
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 26 (6)
Open AccessThe rise in travel-associated measles infections—GeoSentinel, 2015–2019
Measles remains a global threat to human health. In 2018, the World Health Organization (WHO) reported over 328 000 measles cases among 184 WHO member states, with the European Region reporting the most cases (25.6%). 1 From January to March 2019, reported cases rose 300% in comparison to the same months in 2018. 2 Low vaccination coverage for measles is presumed to be responsible for this recent increase. 3–5 International travelers to measles-affected countries are at risk for infection and may contribute to disease importation. 3, 4
- Open Access
- 1 December 2015
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 41, 53-55
Addressing contact tracing challenges—critical to halting Ebola virus disease transmission
- 1 December 2015
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 41, 53-55
Open AccessAddressing contact tracing challenges—critical to halting Ebola virus disease transmission